MiMedx Group, Inc. (NASDAQ:MDXG) Receives Consensus Rating of “Buy” from Analysts

MiMedx Group, Inc. (NASDAQ:MDXG) has been assigned an average rating of “Buy” from the five brokerages that are covering the firm, Marketbeat Ratings reports. Five investment analysts have rated the stock with a buy rating. The average 12-month price target among brokerages that have issued a report on the stock in the last year is $12.00.

Separately, StockNews.com downgraded MiMedx Group from a “strong-buy” rating to a “buy” rating in a report on Friday, November 8th.

Institutional Trading of MiMedx Group

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Harbor Capital Advisors Inc. boosted its position in MiMedx Group by 299.9% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 1,027,738 shares of the company’s stock worth $6,074,000 after purchasing an additional 770,744 shares in the last quarter. Millennium Management LLC boosted its holdings in MiMedx Group by 339.9% during the second quarter. Millennium Management LLC now owns 889,446 shares of the company’s stock worth $6,164,000 after buying an additional 687,267 shares in the last quarter. Dimensional Fund Advisors LP boosted its holdings in MiMedx Group by 47.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,292,822 shares of the company’s stock worth $8,958,000 after buying an additional 413,443 shares in the last quarter. JPMorgan Chase & Co. grew its position in MiMedx Group by 265.4% during the third quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company’s stock valued at $1,757,000 after buying an additional 215,995 shares during the period. Finally, Jane Street Group LLC raised its position in shares of MiMedx Group by 133.6% in the third quarter. Jane Street Group LLC now owns 305,652 shares of the company’s stock worth $1,806,000 after acquiring an additional 174,797 shares during the period. 79.15% of the stock is owned by institutional investors and hedge funds.

MiMedx Group Trading Down 2.7 %

Shares of MiMedx Group stock opened at $8.79 on Friday. MiMedx Group has a 12-month low of $5.47 and a 12-month high of $10.14. The firm’s 50 day simple moving average is $9.21 and its two-hundred day simple moving average is $7.47. The company has a current ratio of 4.10, a quick ratio of 3.53 and a debt-to-equity ratio of 0.10. The firm has a market capitalization of $1.29 billion, a price-to-earnings ratio of 15.98 and a beta of 1.96.

MiMedx Group (NASDAQ:MDXG) last issued its earnings results on Wednesday, October 30th. The company reported $0.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.02. The company had revenue of $84.06 million during the quarter, compared to analyst estimates of $81.00 million. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. During the same quarter last year, the business posted $0.05 EPS. Analysts predict that MiMedx Group will post 0.3 EPS for the current year.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.